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Text 
The lack of Ebola therapies has recently kindled the debate about the possible repurposing of 
approved organotropic (i. e., not etiotropic) drugs for the treatment of this unmet medical 
emergency [1]. The scientific community is now facing an apparently dichotomal opportunity: 
focusing efforts on the time-consuming attempt to develop new drugs [2] or preferring the 
apparently quicker approach of repurposed ones [3]. Of course, each choice would subtract time 
and resources to the other and some scholars fear the possibility that some of the repurposed 
drugs might even worsen the viral pathology by changing the immune response [1]. Probably, 
what we are going to say is trivial, but we wonder if any statistical analysis of the organotropic 
therapies circumstantially used so far by Ebola patients has been done. This study could suggest 
which drugs might be more suited to offer beneficial effect against Ebola, if any. For example, 
some cardiovascular drugs previously demonstrated to be endowed with antiviral properties in 
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vitro [3], might display higher prevalence amongst survived Ebola patients, thus proposing 
themselves as candidates for repurposing. Conversely, the systematic review of the medicines 
assumed in unlucky anecdotes might indicate which drugs should be considered as second choice 
in the above studies.  
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